

## PATIENTS REQUIRED FOR A MULTIPLE SCLEROSIS CLINICAL TRIAL

ATS-MS-1467 is a new drug under development by Apitope Technology (Bristol) Ltd. as a potential new treatment for patients with Relapsing Multiple Sclerosis.

We are currently seeking 18-55 year old male and female patients with Relapsing Multiple Sclerosis (RMS) to join in the trial currently underway in the UK.

Potential patients must also fall within the following criteria:

- ◆ Diagnosed with relapsing multiple sclerosis in the last 10 years
- ◆ Have had one relapse episode in the past 12 months or two relapses in the past 24 months.
- ◆ Have had no Multiple Sclerosis treatment in the last 3 months.

A payment will be made to you for each visit that you attend to compensate you for your time and the inconvenience caused. Further details of this will be provided to you at the consent visit. You will also be reimbursed for reasonable travel expenses and for food and drink during study visits.

**A medical report will be obtained from your consultant and GP prior to any participation in this trial.**

For further information regarding participation this study please contact either your consultant, who may be willing to refer you to your nearest recruiting site in the UK, or the Clinical Trials Co-ordinator (see contact details below here):

Name of lead CTC: Marie Braisher, MS Research Coordinator

Address: National Hospital for Neurology & Neurosurgery, NHNN  
Box 112 Queen Square, London, WC1N 3BG

Telephone number: 0207 692 2363

Email address: [m.braisher@ion.ucl.ac.uk](mailto:m.braisher@ion.ucl.ac.uk)